Upgrade to SI Premium - Free Trial

Bausch Health (BHC) Results 'Good', Solta Could Be Valued at $2.5B+ - Cowen

August 3, 2021 10:54 AM
Cowen analyst Ken Cacciatore reiterated an Outperform rating and $40.00 price target on Bausch Health Companies (NYSE: BHC) following results ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles